Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Announces First Commercial Sale of Unique Ovarian-Cancer-Cell Media
POAI’s TumorGenesis inks deal with top-rated medical university in New England Predictive’s proprietary media allows researchers around the world to isolate, culture ovarian cancer cell types, leading to new targets for treatment The TumorGenesis media retain more than 95% of the DNA and RNA as well as crucial proteomic signatures Predictive Oncology (NASDAQ: POAI) has sold its first-ever commercial order of its novel ovarian cancer cell culture media for cancer cells collected from patient-derived samples (“PDx”) (http://ibn.fm/2xwl6). The sale, made through POAI’s subsidiary TumorGenesis working with distributor US Biological Corporation, marks a milestone for the knowledge-driven company, which is focused on…











